Literature DB >> 26047059

A randomized controlled trial of attention modification for social anxiety disorder.

R Nicholas Carleton1, Michelle J N Teale Sapach1, Chris Oriet1, Sophie Duranceau1, Lisa M Lix2, Michel A Thibodeau1, Samantha C Horswill1, Jordan R Ubbens1, Gordon J G Asmundson1.   

Abstract

Social Anxiety Disorder (SAD) models implicate social threat cue vigilance (i.e., attentional biases) in symptom development and maintenance. A modified dot-probe protocol has been shown to reduce SAD symptoms, in some but not all studies, presumably by modifying an attentional bias. The current randomized controlled trial was designed to replicate and extend such research. Participants included treatment-seeking adults (n = 108; 58% women) who met diagnostic criteria for SAD. Participants were randomly assigned to a standard (i.e., control) or modified (i.e., active) dot-probe protocol condition and to participate in-lab or at home. The protocol involved twice-weekly 15-min sessions, for 4 weeks, with questionnaires completed at baseline, post-treatment, 4-month follow-up, and 8-month follow-up. Symptom reports were assessed with repeated measures mixed hierarchical modeling. There was a main effect of time from baseline to post-treatment wherein social anxiety symptoms declined significantly (p < .05) but depression and trait anxiety did not (p > .05). There were no significant interactions based on condition or participation location (ps > .05). Reductions were maintained at 8-month follow-up. Symptom reductions were not correlated with threat biases as indexed by the dot-probe task. The modified and standard protocol both produced significant sustained symptom reductions, whether administered in-lab or at home. There were no robust differences based on protocol type. As such, the mechanisms for benefits associated with modified dot-probe protocols warrant additional research.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Attention modification protocol; Attentional bias; Longitudinal study; Randomized controlled trial; Social anxiety disorder

Mesh:

Year:  2015        PMID: 26047059     DOI: 10.1016/j.janxdis.2015.03.011

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  7 in total

1.  Insula activation is modulated by attention shifting in social anxiety disorder.

Authors:  Elizabeth R Duval; Sonalee A Joshi; Stefanie Russman Block; James L Abelson; Israel Liberzon
Journal:  J Anxiety Disord       Date:  2018-04-20

2.  Threat-of-shock decreases emotional interference on affective stroop performance in healthy controls and anxiety patients.

Authors:  Tiffany R Lago; Karina S Blair; Gabriella Alvarez; Amanda Thongdarong; James R Blair; Monique Ernst; Christian Grillon
Journal:  Eur J Neurosci       Date:  2019-12-11       Impact factor: 3.698

Review 3.  Attention Bias Modification (ABM): Review of Effects of Multisession ABM Training on Anxiety and Threat-Related Attention in High-Anxious Individuals.

Authors:  Karin Mogg; Allison M Waters; Brendan P Bradley
Journal:  Clin Psychol Sci       Date:  2017-04-26

4.  Effects of cognitive bias modification on social anxiety: A meta-analysis.

Authors:  Haining Liu; Xianwen Li; Buxin Han; Xiaoqian Liu
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

5.  Cognitive bias modification of interpretation in children with social anxiety disorder.

Authors:  Faith Orchard; Adela Apetroaia; Kiri Clarke; Cathy Creswell
Journal:  J Anxiety Disord       Date:  2016-11-06

6.  Does attention bias modification training impact on task performance in the context of pain: An experimental study in healthy participants.

Authors:  Dimitri M L Van Ryckeghem; Stefaan Van Damme; Tine Vervoort
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

7.  Web-Based Cognitive Bias Intervention for Psychiatric Disorders: Protocol for a Systematic Review.

Authors:  Melvyn Zhang; Jiangbo Ying; Guo Song; Daniel Ss Fung; Helen Smith
Journal:  JMIR Res Protoc       Date:  2018-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.